Research
Compare
Two to six companies, their latest annual figures side by side, from SEC filings.
RNACCartesian Therapeutics, Inc.
| Figure | RNACCartesian Therapeutics, Inc.FY2025 · Dec |
|---|---|
| Revenue | $2.80M |
| Revenue, yoy | −92.8% |
| Net income | $130.30M |
| Net income, yoy | −68.3% |
| Net margin | -4,658.6% |
| Free cash flow | $79.40M |
| FCF margin | -2,838.6% |
| EPS, diluted | $5.02 |
Add another company.
Annual · FY2021–FY2025 · USD
From SEC EDGARSame fiscal periods, as filed